Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GNRHR | P30968 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744777 | 0.96 | ALDH1A1 (0.54) | ALDH1A1LMNAPOLBMAPTMAPK1 | |
| SCHEMBL1900261 | 0.88 | ALDH1A1 (0.61) | ALDH1A1LMNAMAPTMAPK1NPSR1 | |
| SCHEMBL1902320 | 0.85 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBMAPTKDM4E | |
| SCHEMBL1902152 | 0.84 | ALDH1A1 (0.49) | ALDH1A1LMNAPOLBMAPTMAPK1 | |
| SCHEMBL3077227 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPTMAPK1NPSR1KDM4E | |
| SCHEMBL3058653 | 0.81 | ALDH1A1 (0.42) | ALDH1A1POLBMAPTMAPK1NPSR1 | |
| SCHEMBL1897557 | 0.81 | RAB9A (0.52) | ALDH1A1MAPTRAB9A | |
| SCHEMBL7739182 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNAPOLBMAPTGAA | |
| SCHEMBL3077801 | 0.75 | ALDH1A1 (0.48) | ALDH1A1MAPTMAPK1NPSR1KDM4E | |
| SCHEMBL1901676 | 0.73 | MEN1 (0.43) | ALDH1A1MAPTMAPK1NPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| EP-1252156-B1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UCL BUSINESS PLC (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | ALDH1A1 1123/4885LMNA 2371/4885POLB 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.